Patent Law Weblog
recent posts
- Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (2026)
- Constellation Designs, LLC v. LG Electronics Inc. (Fed. Cir. 2026)
- Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2026)
- PTAB Reverses § 101 Rejection Where Examiner Failed to Follow the Office’s Own Guidance
- Collision Communications v. Samsung: What Good Did the Government’s Statement of Interest Do?
about
Month: January 2009
-
By Christopher P. Singer — In a Federal Register pre-publication Notice scheduled to be published officially in tomorrow's Federal Register, the U.S. Patent and Trademark Office announced that it plans to hold a roundtable discussion regarding deferred examination options (UPDATE: the notice has now been published in the Federal Register at 74 Fed. Reg.…
-
By Christopher P. Singer — Since the launch of EFS-Web in the fall of 2006, applicants have had the option of e-filing sequence listings as text (.txt) files only, rather than filing sequence listings in both paper and computer readable copies. Several biotech prosecutors in our office have had recent discussion and debate about…
-
By Kevin E. Noonan — Ah, the popular press! Purported protectors of our fundamental freedoms, their behavior (at least in the mainstream press) has recently been less than noble. Eschewing the role of crusader (or even muckraker), the press seems to look for the common popular denominator of received wisdom, and then to trumpet…
-
By Donald Zuhn — On Friday, Geron Corporation announced that the U.S. Food and Drug Administration has approved the biopharmaceutical company's Investigational New Drug (IND) application for the clinical trial of GRNOPC1 in patients with acute spinal cord injury. According to Geron's press release, the clinical trial, to be conducted on patients with complete…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring. Elan Pharma International Ltd. v. Alcon Laboratories, Inc. et al.4:09-cv-00032; filed January 22, 2009 in the Eastern District of Texas Infringement of…
-
By Donald Zuhn — The New York Times reported this evening that Pfizer has agreed in principle to acquire Wyeth for $68 billion. The Times notes that barring an 11th-hour twist, the deal, which would be the largest in the U.S. since March 2006, will be announced tomorrow morning. According to the Times, five…
-
January 26-27, 2009 – Structuring and Negotiating Pharma & Biotech Collaborative Agreements (C5) – London, England January 27-28, 2009 – ITC Litigation (American Conference Institute)*** – Washington, DC January 28-29, 2009 – 6th National Conference on Pharma/Biotech IP Due Diligence (American Conference Institute) – New York, NY January 29, 2009 – Effective Licensing in the…
-
By Jason Derry — Peptimmune and Novartis Sign $500 Million Deal Peptimmune Inc. and Novartis AG recently announced a licensing deal for Peptimmune's multiple sclerosis drug candidate, PI-2301. The deal gives Novartis an exclusive license to the drug candidate. Novartis will assume all responsibilities relative to clinical development, manufacturing, and marketing of PI-2301. The…
-
By Donald Zuhn — The U.S. Patent and Trademark Office announced today that it will be holding Innovation Week 2009 at the Office's headquarters in Arlington, VA from June 22-27. The Patent Office describes Innovation Week 2009 as a weeklong celebration of the vital role patents and the USPTO play in our economy and…
-
FX Conferences will be offering an audio conference entitled "Effective Licensing in the Wake of MedImmune v. Genentech" on January 29, 2009 from 11:30 AM to 12:30 PM (EDT). Dr. Michael Samardzija of Bracewell & Giuliani will explore the Supreme Court's decision in MedImmune v. Genentech, and the various decisions that have followed it, and…
Patent Docs 